Assignee: Cancer Research Technology Limited

Location: London, GB
No. of patents: 55

Number	Title	Issue Date
8148087	Detection of dysplastic or neoplastic cells using anti-MCM6 antibodies Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polype...	04/03/2012
8105782	Materials and methods relating to nucleic acid amplification and profiling The invention provides improved methods for determining the methylation profile of a nucleic acid sequence and for determining one or more base changes in the target nucleic acid sequence as compared to a corresponding control sequence. The methods are one-step meth...	01/31/2012
8058045	Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amin...	11/15/2011
7951819	Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc. The present invention also pert...	05/31/2011
7868040	Anti-cancer combinations The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and an alkylating agent, which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-...	01/11/2011
7868039	Anti-cancer combinations The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vinca alkaloids, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dim...	01/11/2011
7863322	Anti-cancer combinations The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites an...	01/04/2011
7863321	Anti-cancer combinations The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention rela...	01/04/2011
7863320	Anti-cancer combinations The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a platinum compound which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-d...	01/04/2011
7816334	Materials and methods relating to immune responses to fusion proteins The invention provides nucleic acid construct and nucleic acid expression vectors directing the expression of a fusion protein consisting of a disease peptide antigen and a first domain of FrC of tetanus toxin. The invention provides nucleic acid (DNA) vaccines for ...	10/19/2010
7771930	Cancer The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers. ...	08/10/2010
7745638	3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3....	06/29/2010
7740830	Imaging, diagnosis and treatment of disease The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium. ...	06/22/2010
7732483	DNA-PK inhibitors A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7...	06/08/2010
7700822	Modulation of cytochrome P450 reductase activity The present invention relates to non-human transgenic animals, tissues and/or cells derived therefrom having depleted or ablated cytochrome P450 reductase (CPR) expression, methods of producing such animals, tissues and/or cells, and methods of using such animals, t...	04/20/2010
7696204	Pharmaceutical compounds Pyrimidines of formula (I): wherein R1 to R4, X and Y are defined in the specification are inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, fun...	04/13/2010
7696203	DNA-PK inhibitors Compounds of formula I: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N; and (iii) CH, O, C; the dotted lines repre...	04/13/2010
7674823	DNA-PK inhibitors The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1 and R2 are indepen...	03/09/2010
7662625	Methods for detecting the differentiation status of cells using 5T4 antigen expression The present invention relates to methods for detecting the differentiation status of stem cells comprising detecting the expression of 5T4 antigen in said stem cells. The present invention also relates to methods for separating populations of undifferentiated or dif...	02/16/2010
7626011	Antibodies against tumor surface antigens The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibod...	12/01/2009
7612079	2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof wherein R2 is 2-hydroxymethylpyrrolidin-1-yl, or NHCH(R4)CH(R3)OH, wherein ...	11/03/2009
7582642	Purine derivatives The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H;	09/01/2009
7582440	Imaging, diagnosis and treatment of disease The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium. ...	09/01/2009
7563818	Photosensitizer functionalised nanoparticles The present invention relates to self-assembly of a photosensitizer on a nanoparticle. The invention also provides methods for production of functionalized (eg. stabilized) nanoparticles. The nanoparticles may be used in Photodynamic Therapy (PDT). The invention can...	07/21/2009
7544689	Purine derivatives The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H;	06/09/2009
7531530	Therapeutic compounds The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments. ...	05/12/2009
7510830	Cancer treatment by combination therapy Methods and compositions are provided for treating cancer, the methods including the step administering, either sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of compounds, and (ii) at least one compound selected from compounds wh...	03/31/2009
7498034	Imaging, diagnosis and treatment of disease The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascu lar endothelium. ...	03/03/2009
7462642	Anti-cancer combinations The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumor activity. M...	12/09/2008
7459157	Detection of dysplastic or neoplastic cells using anti-MCM2 antibodies Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polype...	12/02/2008
7410643	Materials and methods relating to fusion proteins for inducing an immune response A nucleic acid construct is provided for delivery into living cells in vivo for inducing an immune response in a patient to an antigen; the construct directing the expression of a fusion protein, said fusion protein comprising said antigen and an adjuvant sequence d...	08/12/2008
7402607	DNA-PK inhibitors A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, ...	07/22/2008
7351701	Therapeutic compounds The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments. ...	04/01/2008
7323562	Method of preparing poly(ADP-ribose) polymerases inhibitors This invention relates to a new and convergent route to small molecule inhibitors of poly(ADP-ribose) polymerase, such as 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, via a key Sonogashira coupling reaction and a CuI...	01/29/2008
7312082	Crystal structure of G-quadruplex containing a potassium ion The present invention relates to a crystal structure of G-quadruplexes and its use. The invention provides a crystal of an intramolecular G-quadruplex structure having a hexagonal space group P6, and unit cell dimensions a=b=56.7 and c=42.1; α=β=90°, γ=120° and...	12/25/2007
7307099	4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents This invention pertains to certain 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds, and analogs thereof, including compounds of the following formula, which are, inter alia, antiproliferative agents, anticancer agents, and/or thioredoxin/t...	12/11/2007
7300930	Therapeutic acridone and acridine compounds The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ═O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a doubl...	11/27/2007
7268126	Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-ce]indol-6-one The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a compo...	09/11/2007
7241618	Expression system The present invention provides a polynucleotide comprising a RNA polymerase III promoter, a region encoding a siRNA, and a transcriptional termination element comprising five consecutive thymine residues. The invention also provides for vectors, cells and non-human ...	07/10/2007
7235585	Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs This invention pertains to certain enzyme (CPG2) activated self-immolative nitrogen mustard prodrugs, which are useful in enzyme prodrug therapy (EPT), such as ADEPT and GDEPT, for the treatment of proliferative conditions, such as cancer, and which have the followi...	06/26/2007

«First «Previous1 2 Next»Last»

PatentStorm

Celebrity Inventors

PatentStorm News

Assignee: Cancer Research Technology Limited